SLC 022Alternative Names: Glial cell modulator - Solace Pharmaceuticals; SLC022
Latest Information Update: 29 Jun 2015
At a glance
- Originator Solace Pharmaceuticals
- Mechanism of Action Glial cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postherpetic neuralgia
Most Recent Events
- 12 Jan 2009 Phase-II clinical trials in Postherpetic neuralgia in USA and Germany (PO)